spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
benefix
pfizer europe ma eeig - nonacog alfa - hemofilia b - hemostaatit - verenvuodon hoito ja ehkäisy hemofilia b-potilailla (synnynnäinen tekijä ix: n vajaus).
levofolic 50 mg/ml injektio-/infuusioneste, liuos
medac gesellschaft fÜr klinische spezialprÄparate mbh - disodium levofolinate - injektio-/infuusioneste, liuos - 50 mg/ml - natriumlevofolinaatti
paracetamol teva 1000 mg tabletti
teva b.v. - paracetamol - tabletti - 1000 mg - parasetamoli
paracetamol teva 500 mg tabletti, kalvopäällysteinen
teva b.v. - paracetamol - tabletti, kalvopäällysteinen - 500 mg - parasetamoli
obizur
baxalta innovations gmbh - susoctocog alfa - hemofilia a - hemostaatit - verenvuototapahtumien hoito potilailla, joilla on hankittu hemofilia, jotka ovat aiheuttaneet vasta-aineita tekijälle viii. obizur on tarkoitettu aikuisille.
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
zostavax
merck sharp & dohme b.v. - varicella-zoster-virus (elävä, heikennetty) - herpes zoster; immunization - virustartunnat - zostavax on tarkoitettu herpes zosterin (zosterin tai vyöruusu) ja herpes-zoster-sidekalvon jälkeisen hermosairauden. zostavax on tarkoitettu immunisointiin henkilöille, jotka ovat 50-vuotiaita tai vanhempia.
stocrin
merck sharp & dohme b.v. - efavirentsi - hiv-infektiot - antiviraalit systeemiseen käyttöön - stocrin ilmoitetaan antiviraalinen yhdistelmähoito ihmisen-hi-virus-1 (hiv-1)-tartunnan saaneiden aikuisten, nuorten ja lasten kolme vuotta täyttäneille. stocrinia ei ole tutkittu riittävästi potilailla, joilla on pitkälle edennyt hiv-tauti eli potilailla, joiden cd4-arvo on < 50 solua/mm3, tai kun vika proteaasi-inhibiittori (pi)-sisältävät hoito-ohjelmat. vaikka ristiresistenssiä efavirentsin ja proteaasinestäjien kesken ei ole dokumentoitu, tällä hetkellä ei ole riittävästi tietoa tehoa myöhempää käyttöä pi-pohjainen yhdistelmä hoidon jälkeen epäonnistuminen hoito sisältää stocrinin.